Form 6-K Altamira Therapeutics For: May 19
- Stocks tumble after weak U.S. confidence data; oil gains
- Earnings Estimates are 'Likely Too Optimistic', Risk Not Fully Reflected - Goldman
- Pinterest (PINS) CEO Silbermann Is Stepping Down, Shares Gain 8%
- Apple's (AAPL) Runs into 5G Modem Development Issues, Will Continue to Use Qualcomm (QCOM) - Analyst
- Bank of America Clients are Selling This Rally
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May, 2022
Commission File Number: 001-36582
Altamira Therapeutics Ltd.
(formerly Auris Medical Holding Ltd.)
(Exact name of registrant as specified in its charter)
Clarendon House, 2 Church Street
Hamilton HM 11, Bermuda
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Yes ☐ No ☒
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Yes ☐ No ☒
Annual General Meeting Results
On May 19, 2022, Altamira Therapeutics Ltd. (the “Company”) held its Annual General Meeting of Shareholders. Based on the presence in person or by proxy of holders of the Company’s outstanding ordinary shares constituting a quorum, each of the agenda items submitted to a vote of the shareholders was duly adopted by the requisite majority in accordance with the Company’s Bye-Laws:
Agenda Item 1: Re-election of the Members of the Board of Directors
The Company’s shareholders re-elected Messrs. Thomas Meyer, Armando Anido, Alain Munoz, Mats Peter Blom and Ms. Margrit Schwarz, as members of the Board of Directors, each for a term of one year ending upon completion of the 2023 Annual General Meeting (or until their respective successors are elected).
Agenda Item 2: Appointment of Auditors
The Company’s shareholders re-elected Deloitte AG, Switzerland, as auditors of Altamira Therapeutics Ltd. for the 2022 financial year.
Agenda Item 3: Compensation of the Board of Directors and the Executive Officers
The Company’s shareholders approved, on a non-binding advisory basis, the 2021 Board of Directors’ and Executive Officers’ compensation.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|Altamira Therapeutics Ltd.|
|Date: May 19, 2022||By:||/s/ Thomas Meyer|
|Title:||Chief Executive Officer|
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Altamira Therapeutics (CYTO) Granted FDA 510(k) Clearance for Bentrio to Treat Allergic Rhinitis
- Fidelity Life: 4 Living Benefits of Life Insurance
- EDM Announces Change of CFO and Annual General Meeting
Create E-mail Alert Related CategoriesSEC Filings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!